Renalytix PLC Total Voting Rights (7147D)

TIDMRENX

RNS Number : 7147D

Renalytix PLC

01 July 2021

Renalytix plc

("Renalytix" or the "Company")

Total voting rights

The Company's total issued share capital consists of 72,197,286 shares of 0.25 pence each, with each share carrying the right to one vote. Renalytix does not hold any shares in treasury. The total number of voting rights in the Company following Admission will therefore be 72,197,286.

The figure of 72,197,286 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

 
Renalytix plc                                             www.renalytix.com 
James McCullough, CEO                                       Via Walbrook PR 
 
Stifel (Nominated Adviser, Joint Broker)                 Tel: [phone] 
Alex Price / Nicholas Moore 
 
Investec Bank plc (Joint Broker)                         Tel: [phone] 
Gary Clarence / Daniel Adams 
 
Walbrook PR Limited          Tel: [phone] or [e-mail] 
Paul McManus / Lianne Cawthorne                  Mob: [phone] / 07584 
                                                                    391 303 
 
 

About Kidney Disease

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and one out of two people with very low kidney function who are not on dialysis do not know they have CKD.(1) Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

About KidneyIntelX

KidneyIntelX, is a first-of-kind, bioprognostic(TM) platform that employs a proprietary artificial intelligence-enabled algorithm to combine diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com ). For more information, visit www.renalytix.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRDKKBPQBKDPAN

(END) Dow Jones Newswires

July 01, 2021 02:00 ET (06:00 GMT)